ECO Animal Health Group plc (LON:EAH), a leader in the development, registration and marketing of pharmaceutical products for global animal health markets, has provided an update to its expected results for the year ended 31 March 2023.
The ECO Group has experienced strong trading in its final quarter and it is clear that the demand for Aivlosin has been a little stronger than expected in China and Asia. As a result, the Board now expects that Revenue and Earnings before Interest, Tax, Depreciation and Amortisation will be slightly ahead of market expectations for the current financial year.
David Hallas, ECO Animal Health CEO, noted that “Our business has delivered good progress in key international markets especially Asia. We look forward to providing a further update following the completion of the financial year.”
ECO Animal Health Group plc researches, develops and commercialises products for livestock. Our business strategy is to generate shareholder value by achieving the maximum sales potential from the existing product portfolio whilst investing in Research and Development (“R&D”) for new products, particularly vaccines, and seeking to in-license new products.
